Acurx Pharmaceuticals, Inc.
NASDAQ Capital MarketTotal Valuation
Acurx Pharmaceuticals, Inc. carries a market capitalization of 6.39M, placing it among publicly traded companies globally. Its enterprise value stands at -3.99M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 6.39M |
| Enterprise Value | -3.99M |
Share Statistics
Acurx Pharmaceuticals, Inc. currently has 4.30M shares outstanding.
| Shares Outstanding | 4.30M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 0.82 |
| P/TBV Ratio | 0.82 |
| P/FCF Ratio | -0.72 |
| P/OCF Ratio | -0.72 |
Financial Position
Acurx Pharmaceuticals, Inc. maintains a current ratio of 3.88, meaning it holds 3.9x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 3.88 |
| Quick Ratio | 3.80 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -128.11 |
| Return on Assets (ROA) | -87.57 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Acurx Pharmaceuticals, Inc.'s stock has declined approximately -83.50072% over the past 52 weeks. The 50-day moving average sits at 1.37, while the 200-day moving average is 2.05.
| Beta (5Y) | N/A |
| 52-Week Price Change | -83.50072% |
| 50-Day Moving Average | 1.37 |
| 200-Day Moving Average | 2.05 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -7.67M, while operating income came in at -7.67M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -7.67M |
| Pretax Income | -7.51M |
| Net Income | -7.51M |
| EBITDA | -7.67M |
| EBIT | -7.67M |
| Earnings Per Share (EPS) | -2.62 |
Balance Sheet
Total book value stands at 8.15M, with working capital of 8.15M providing operational flexibility.
| Cash & Cash Equivalents | 10.66M |
| Total Debt | N/A |
| Net Debt | -10.66M |
| Equity (Book Value) | 8.15M |
| Book Value Per Share | 1.90 |
| Working Capital | 8.15M |
Cash Flow
Acurx Pharmaceuticals, Inc. produced -6.18M in operating cash flow over the past twelve months.
| Operating Cash Flow | -6.18M |
| Capital Expenditures | N/A |
| Free Cash Flow | -6.18M |
| FCF Per Share | -2.16 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -161.76 |
| FCF Yield | -139.10 |
Stock Splits
Acurx Pharmaceuticals, Inc.'s most recent stock split took place on August 5, 2025 with a 20:1 split ratio.
| Last Split Date | 8/5/2025 |
| Split Ratio | 20:1 |
Scores
Acurx Pharmaceuticals, Inc. posts an Altman Z-Score of -10.10, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -10.10 |